Blog Archives

The phenotype broker: Blockchain and patient phenotype

July 26, 2019 – “Blockchains for secure digitized medicine”. This is the title of a very interesting and important article in the Journal of Personalised Medine (JPM) as of May 28, 2019.

Blockchain as an emerging technology (particularly around the hype on Bitcoins) has been gaining in popularity,

Read more ›

Tags: , , , , , , , , , , , , , , , , ,

Direct-to-Consumer Genetic Testing: Are Patients Ready?

March 31, 2018 – Are patients ready for direct-to-consumer genetic testing?  This was the very important and central question that came up in the article by Matt Smith on Medscape, published March 29, 2018.

Since thasso is all about theragenomic and personalized medicine  and individualized drug safety (i.e.

Read more ›

Tags: , , , , , ,

Precision Medicine Initiative: draft guidances issued

July 9, 2016 – This is a huge step into the future of theragenomic and personalized medicine and individualized drug safety. In support of the President’s Precision Medicine Initiative (PMI), the American Food & Drug Administration (FDA) just issued two draft guidances that,

Read more ›

Tags: , , , , , , ,

Theragenomic Medicine: Palbociclib (Ibrance) approved for postmenopausal women with advanced (metastatic) breast cancer

February 8, 2015 – The American Food and Drug Administration (FDA) has granted accelerated approval to Palbociclib (Ibrance) to treat advanced (metastatic) breast cancer.  The FDA granted Ibrance breakthrough therapy designation because the sponsor demonstrated through preliminary clinical evidence that the drug may offer a substantial improvement over available therapies.

Read more ›

Tags: , , , , , ,

India steps closer to Personalized Medicine

July 01, 2014 – As the knowledge of genetics and genomics rapidly expand, a personalized approach to health care is becoming increasingly important. India is fast becoming a promising contender in the global healthcare arena The majority of the global healthcare industry is ready to offer solutions for the masses.

Read more ›

Tags: , , ,

The Apomediary [Patient Expert] and Personalized Medicine: A Commentary

June 22, 2014 – The individuum (i.e., patient) is the phenotype expert on her/his individualized form of proper disease she/he is suffering from. It is not her/his treating physician, it is not a regulatory person concerned with the safety and efficacy of the medication geared towards treating her/his condition,

Read more ›

Tags: , , , , , , , , , , , , , ,

Apple plan to revolutionize mobile healthcare: Personalized medicine at the horizon on the iPhone and the likes

Apple has unveiled HealthKit, a platform to centralise data from different types of devices, like fitness trackers, heart rate and blood pressure monitors.

iphone healthLaunching iOS 8 for iPhones and iPads, which it describes as the biggest release since the launch of the App Store,

Read more ›

Tags: , , ,

FDA approves Siltuximab [Sylvant] for rare Castleman’s disease

April 23, 2014 – The U.S. Food and Drug Administration today approved Sylvant (siltuximab) to treat patients with multicentric Castleman’s disease (MCD), a rare disorder similar to lymphoma (cancer of the lymph nodes).

MCD causes an abnormal overgrowth of immune cells in lymph nodes and related tissues in the body.

Read more ›

Tags: , , , , , , ,

Can We Identify Risk for Drug Toxicity?

October 10, 2013 – Very recently, David Kerr, Professor of Cancer Medicine at University of Oxford, in the United Kingdom, and past President of the European Society for Medical Oncology, talked on Medscape (see the video here) about risk-benefit analyses for novel, inventive cancer treatments. See here in italics his statement:

 When we talk about precision medicine and personalized medicine,

Read more ›

Tags: , , , , , , , , , , , , ,

EMA: Public consultation open on concept paper on pharmacogenomics in evaluation of authorised medicines

January 26, 2012 – I am relaying the information below by the EMA to the readers of this blog. It might be interessting to dwell into this concept paper (as a scientist, a treating physician, or an informed patient) for informations only or even for commenting.

__________________

 The European Medicines Agency (EMA) has released a concept paper on the development of a guideline on the evaluation of pharmacogenomic methodologies in the evaluation of authorised medicines for public consultation.

Read more ›

Tags: , , , , ,

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Development and analytical validation of a next-generation sequencing based microsatellite instabili October 18, 2019
    The referenced article describes an assay that has a clinically relevant five-day turnaround time and can be conducted on as little as 20 ng genomic DNA with a batch size of up to forty samples in a single run.
  • Lifestyle is a threat to gut bacteria: Ötzi proves it October 18, 2019
    The intestinal microbiome is a delicate ecosystem made up of billions and billions of microorganisms, bacteria in particular, that support our immune system, protect us from viruses and pathogens, and help us absorb nutrients and produce energy. The industrialization process in Western countries had a huge impact on its content. This was confirmed by a […]
  • Singapore completes whole genome sequencing analysis of multi-ethnic Asian populations October 18, 2019
    A new genetic databank has been established containing the completed whole-genome sequencing (WGS) data of close to 5,000 Singaporeans. Worldwide, WGS is increasingly used in research and healthcare to identify genetic variations using cutting-edge technologies that allow large numbers of individuals to be sequenced rapidly—This new study is the world's largest WGS analysis of Asian […]
  • Researchers quantify limitations of health reports from direct-to-consumer genetic tests October 17, 2019
    Health reports from direct-to-consumer (DTC) genetic tests that use a limited variant screening approach often yield clinical false-negative results, which pose the risk of informing health care decisions based on incomplete information, according to findings presented at the American Society of Human Genetics (ASHG) 2019 Annual Meeting in Houston, Texas.
  • Researchers develop mouse model of human gene involved in Alzheimer's disease October 17, 2019
    In research that helps scientists better understand and explore treatments for diseases like Alzheimer's, scientists have developed a line of mice in which the mouse version of the Alzheimer's-associated MAPT gene has been fully replaced by the human version of the gene. In this new animal model, known as a full gene-replacement model, the MAPT […]
Top